Clinical Trials Logo

Prostatic Neoplasms clinical trials

View clinical trials related to Prostatic Neoplasms.

Filter by:

NCT ID: NCT06452212 Not yet recruiting - Clinical trials for Metastatic Hormone-Sensitive Prostate Cancer

Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients

Start date: July 31, 2024
Phase:
Study type: Observational

The purpose of this study is to establish an expert consensus recommendations on managing patients with mHSPC in South Korea, and to provide clinicians with a comprehensive guide to support their clinical decision making. There are no secondary objectives for this study.

NCT ID: NCT06451614 Not yet recruiting - Prostate Cancer Clinical Trials

SpaceIT Hydrogel System for Perirectal Spacing

HYDROSPACE
Start date: October 1, 2024
Phase: N/A
Study type: Interventional

To evaluate the safety and effectiveness of the SpaceITâ„¢ Hydrogel System in patients undergoing External Beam Radiotherapy (EBRT) for the treatment of prostate cancer.

NCT ID: NCT06451445 Recruiting - Prostate Cancer Clinical Trials

A Pan-Canadian, Investigator Initiated Clinical Trial With Focal IRE Directed to Intermediate-Risk Prostate Cancer

WIRED
Start date: May 16, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to investigate the safety and efficacy of Irreversible Electroporation (IRE) using NanoKnife technology in patients with intermediate-risk prostate cancer. This patient population was chosen because they would otherwise be treated with conventional therapies with high side effects. The main questions it aims to answer are: 1. Is the NanoKnife system is effective at damaging prostate tumour cells, and killing the cancer? 2. Are there any safety concerns with the procedure, or major side effects caused by the treatment? Participants will undergo IRE treatment with the NanoKnife system, and then complete follow-up appointments for 12-months after the procedure.

NCT ID: NCT06450548 Not yet recruiting - Clinical trials for Prostate Cancer Metastatic

Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis Prior to 177Lu-PSMA

PYPET
Start date: June 15, 2024
Phase: N/A
Study type: Interventional

Prostate cancer is a significant health issue, representing 21.8% of male cancer cases in France with over 449,000 new cases in 2018. It's the cause of 10% of cancer deaths in Europe. The PSMA is a target for mCRPC treatment, with therapies like 177Lu-PSMA-617 delivering radiation to cancer cells. The Vision study showed that 177Lu-PSMA-617, combined with standard care, improved survival rates significantly compared to standard care alone.The French ANSM authorized 177Lu-PSMA-617 for mCRPC under certain conditions. Patients must have histologically confirmed mCRPC, be progressive despite treatment, and have PSMA-positive imaging. Imaging assessments include PSMA PET/CT and 18F-FDG PET/CT to identify FDG-positive and PSMA-negative sites, which are associated with a poorer prognosis. Parametric analysis using dynamic PET could improve lesion characterization, aiding in treatment decisions. This is the focus of the PyPET study. The main objective focuses on a comparative analysis of data from dynamic parametric analysis (metabolic influx rate Ki, volume of distribution Vd) and static analysis (standard at 1 hour) using 18F-FDG and 68Ga-PSMA PET/CT for diagnosing metastases, especially in the liver, lymph nodes, and bones. It aims to assess the effectiveness of these imaging techniques in accurately identifying metastatic sites.

NCT ID: NCT06450106 Not yet recruiting - Prostate Cancer Clinical Trials

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

Start date: September 2024
Phase: Phase 1
Study type: Interventional

A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

NCT ID: NCT06449781 Not yet recruiting - Prostate Cancer Clinical Trials

177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer

PSMA-ADJUVO
Start date: June 2024
Phase: Phase 2
Study type: Interventional

Single-center, non-commercial phase 2 clinical trial to evaluate 177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment using locoregional teleradiotherapy and hormone therapy

NCT ID: NCT06449664 Recruiting - Prostate Cancer Clinical Trials

Training for Men Undergoing Androgen Deprivation Therapy.

ADT-train
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the effects of a newly developed training concept on men with prostate cancer undergoing androgen deprivation therapy (ADT). The main questions it aims to answer are: - How feasible and safe is the new training concept? - How efficient is the training concept to counteract side effects caused by ADT? Researchers will compare the new training concept with usual care to evaluate how efficient the training concept is to counteract the ADT-related side effects. Participants in the intervention group will perform the new training concept twice weekly for 12 weeks. Participants in the control group will only receive usual care. All participants will visit the laboratory at baseline and after 6 and 12 weeks to measure the primary and secondary outcomes.

NCT ID: NCT06446401 Not yet recruiting - Prostate Cancer Clinical Trials

The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer

Lead4Care
Start date: June 3, 2024
Phase:
Study type: Observational

Lead4Care is an observational, open-label, multicenter study evaluating the effectiveness, tolerance, and cost-effectiveness of triple against double therapy in matched groups of mHSPC patients with high tumor burden. In addition to androgen deprivation therapy (ADT), the triple constitutes of docetaxel and novel hormonal therapy (NHT), and the double of NHT therapy in addition to ADT. Their effectiveness is compared in terms of mortality and morbidity, which is captured by HRQoL, pain, fatigue. Potential side effects are captured by neuropathy, diarrhea, constipation, anxiety, sickness, and dyssomnia. The cost-effectiveness is evaluated within a Markov model from a societal perspective in which the main disease stages are mHSPC, mCRPC and death. In connection with a regular visit in hospital care, prostate cancer patients who in addition to ADT will initiate double or triple therapy are offered participation in the study. If they consent on-line, they will receive 13 online surveys over a 60-month period. The surveys are sent with an interval of two months for the first six months, quarterly thereafter until two years, and thereafter yearly. Once all participants have been recruited, the baseline data shared by healthcare personnel and patients will be enriched with registry data. This baseline and registry data involves information about the patients' historical and current health- and socioeconomic status. Thereby, Lead4Care will be able to identify comparable groups of patients on triple and double treatments by using advanced matching methods. In order to assure an objective analysis, Lead4Care will not allow any data extraction until Lead4Care has predefined and published all details regarding the comparison. The existing protocol is then complemented with information on exactly which patients will be compared across triple and double therapy, and how outcomes will be compared. For these treatments, the main objectives are to: - Compare mortality and morbidity on triple and double therapy, and their relative side-effects. - Capture patient preferences for these different treatment outcomes over time. - Evaluate cost-effectiveness of triple versus double therapy from a societal perspective.

NCT ID: NCT06441994 Recruiting - Prostate Cancer Clinical Trials

Clinical Trial of Targeted Alpha Therapy for Prostate Cancer

Alpha-PS1
Start date: May 24, 2024
Phase: Phase 1
Study type: Interventional

PSW-1025 is administered intravenously to patients with castration-resistant prostate cancer to evaluate its tolerability, safety, pharmacokinetics, absorbed dose, and efficacy, as well as to determine the recommended dose for Phase II.

NCT ID: NCT06441292 Not yet recruiting - Prostate Cancer Clinical Trials

Multi-Modal Image Fusion for Precision Prostate Biopsy Navigation

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

This study is a prospective randomized controlled clinical trial aimed at comparing the detection rates of clinically significant prostate cancer between conventional biopsy methods and AI-assisted biopsy methods in patients undergoing initial prostate biopsy who meet the indications for prostate biopsy.